Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common bleeding drug cut transfusions after hip fractures?

NCT ID NCT03063892

Disease control Sponsor: Gregory M Georgiadis MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This trial investigates whether tranexamic acid (TXA), a drug that helps control bleeding, can reduce the need for blood transfusions in people over 60 who have hip fractures and require surgery. Participants receive either TXA or a placebo (saline) before, during, and after surgery. The study measures how many patients need a blood transfusion and how much blood is lost during the operation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tranexamic acid (TXA)
What this could lead to
If it works, this could reduce the need for blood transfusions after hip fracture surgery, lowering risks and recovery time.
What could go wrong
This is a small, early-phase trial. TXA may not reduce transfusions significantly, and there is a small risk of blood clots or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2017

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Over the age of 60 years * Hip fracture requiring surgical intervention * Signs consent and agrees to participate Exclusion Criteria: * Under the age of 60 * Does not sign consent or refuses participation * Known hypersensitivity to tranexamic acid * Multiple acute fractures * Creatinine clearance \<30 * History of seizures * Active hormone therapy * History of coagulation abnormality * History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last year or history or recurrent DVT/PE * Myocardial infarction (MI) and/or stents within the past year * History of intracranial hemorrhage * Acquired defective color vision * Patients admitted directly to nursing units or surgery without stay in the Emergency Center * Patients who sustain fracture while hospitalized at ProMedica Toledo Hospital

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hip fractures are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hip fracture

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hip fractures

Contacts and locations

Locations

  • ProMedica Toledo Hospital

    Toledo, Ohio, 43606, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.